This activity has expired. Thank you for using WebBasedCME.com. Continue to check our activities page for additional online CME offerings .


POST-TEST - Managing FPG and PPG With Incretin-Based Therapies: A Therapeutic Double Play


INSTRUCTIONS: Select the most appropriate response. To receive credit, participants must earn a score of 70% or higher.

0. Have you created an account on WebBasedCME.com? You must register and be signed in to participate and receive CME credit for this activity.



1. Which of the following statements is true?
A: As A1C gets closer to target, fasting plasma glucose (FPG) has a bigger effect on A1C than postprandial plasma glucose (PPG).
B: As A1C gets closer to target, PPG has a bigger effect on A1C than FPG.
C: As A1C gets closer to target, FPG and PPG contribute equally to A1C .
D: As A1C gets closer to target, neither FPG nor PPG affect A1C.

2. ___________ insulin secretion and ____________ glucagon secretion in the postprandial period contribute to postprandial hyperglycemia.
A: Decreased, increased
B: Increased, decreased
C: Increased, increased
D: Decreased, decreased

3. The incretin effect refers to which of the following?
A: Intravenous glucose is a more potent stimulator of glucagon secretion than oral glucose.
B: Oral glucose is a more potent stimulator of glucagon secretion than intravenous glucose.
C: Intravenous glucose is a more potent stimulator of insulin secretion than oral glucose.
D: Oral glucose is a more potent stimulator of insulin secretion than intravenous glucose.

4. Which of the following statements about incretin hormones is NOT true?
A: They augment insulin secretion at physiologic concentrations.
B: Their effects are glucose dependent.
C: GIP reduces postprandial glucagon and delays gastric emptying.
D: GLP-1 is a more potent insulin secretagogue in people with type 2 diabetes.

5. Which of the following best describes the relationship between GLP-1 and glucagon?
A: GLP-1 suppresses glucagon in a glucose-dependent manner.
B: GLP-1 suppresses glucagon, regardless of glucagon level.
C: GLP-1 increases glucagon in a glucose-dependent manner.
D: GLP-1 increases glucagon, regardless of glucagon-level.

6. In type 2 diabetes, _____ response is preserved, and ______ response is defective.
A: GIP, GLP-1
B: GLP-1, GIP
C: GIP, GIP
D: GLP-1, GLP-1

7. Average improvement in A1C with DPP-4 inhibitors is approximately:
A: 0.8%
B: 1.2%
C: 1.5%
D: 1.8%

8. Incretin mimetic inhibitors improve which of the following outcomes?
A: FPG only
B: PPG only
C: FPG and PPG
D: Neither FPG nor PPG

9. DPP-4 inhibitors provide _______________ levels of GLP-1 and incretin mimetics provide ___________________.
A: Physiologic, pharmacologic
B: Pharmacologic, physiologic
C: Physiologic, physiologic
D: Pharmacologic, pharmacologic

10. Which of the following in NOT true of incretin mimetics?
A: They are given as a subcutaneous injection.
B: They are associated with weight loss.
C: They are associated with improvements in A1C, FPG, and PPG.
D: They are associated with an increase in triglycerides.

Return to Activity